FDA Class III recall: buprenorphine 2 mg tablets, label mix-up

The FDA lists a Class III recall, dated 9 September and still ongoing, of buprenorphine 2 mg sublingual tablets in 30-tablet unit-dose packs distributed by American Health Packaging, for a labelling mix-up. Class III is the lowest recall category, used when a product is unlikely to cause adverse health consequences.

The notice concerns one US distributor's unit-dose packaging; it says nothing about supply elsewhere. For services dispensing unit-dose buprenorphine, the practical step is to check pack labels against contents at the point of administration, which is good practice for any controlled drug.

• Check the label and strength on unit-dose buprenorphine packs against the prescription at each administration.
• Report any suspected label or strength discrepancy through your local incident and pharmacovigilance systems.
• Ask patients on buprenorphine to report tablets that look different from their usual supply.
• Recognise that Class III is the lowest recall tier and does not signal a safety finding about the drug itself.

Why it matters

A strength or label error on an opioid agonist can cause under-dosing and withdrawal, so packaging checks matter even when the recall tier is low.

Don't overread it

This is an administrative packaging recall, not a safety finding about buprenorphine.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.